Acknowledgement to Referees
- PDF / 352,114 Bytes
- 3 Pages / 595.276 x 790.866 pts Page_size
- 95 Downloads / 190 Views
ACKNOWLEDGEMENT TO REFEREES
© Springer Nature Switzerland AG 2020
Dear Reader, Welcome to the final issue of European Journal of Drug Metabolism and Pharmacokinetics for 2020. This year has presented many challenges and I would like to take this opportunity to thank all who have contributed to ensuring the journal has thrived despite the extraordinary circumstances that the science community, and the world in general, has faced. The COVD-19 pandemic has reinforced the importance of rapid and wide dissemination of high-quality information. Springer Nature is supporting the global response to COVID-19 by making all relevant content immediately and freely available. Indeed, European Journal of Drug Metabolism and Pharmacokinetics has published a number of papers relevant to the COVID-19 pandemic that are free to access. I would like to start by thanking the authors of the articles published in European Journal of Drug Metabolism and Pharmacokinetics over the course of 2020. The enthusiasm of all authors for their chosen fields and their willingness to contribute content to the journal are crucial for its continued success. 2020 was a successful year for European Journal of Drug Metabolism and Pharmacokinetics. Over 60 articles have been published; the most popular of these, in terms of downloads from SpringerLink, have been: • Tarek, M., Savarino, A. Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for
Therapy and Prevention. Eur J Drug Metab Pharmacokinet (2020). https://doi.org/10.1007/s13318-020-00640-6
• Perkins, D., Butler, J., Ong, K. et al. A Phase 1, Randomised, Placebo-Controlled, Dose Escalation Study to Investigate the
Safety, Tolerability and Pharmacokinetics of Cannabidiol in Fed Healthy Volunteers. Eur J Drug Metab Pharmacokinet 45, 575–586 (2020). https://doi.org/10.1007/s13318-020-00624-6 • Muehler, A., Kohlhof, H., Groeppel, M. et al. Safety, Tolerability and Pharmacokinetics of Vidofludimus calcium (IMU838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects. Eur J Drug Metab Pharmacokinet 45, 557–573 (2020). https://doi.org/10.1007/s13318-020-00623-7 • Thémans, P., Belkhir, L., Dauby, N. et al. Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization. Eur J Drug Metab Pharmacokinet (2020). https://doi.org/10.1007/s13318-020-00648-y • Shennak, M., Al-Jaouni, R., Kshirasagar, S. et al. An Open-Label, Randomized, Single-Dose, Crossover, Comparative Pharmacokinetics Study of YLB113 and the Etanercept Reference Product in Healthy Adult Male Subjects. Eur J Drug Metab Pharmacokinet 45, 467–475 (2020). https://doi.org/10.1007/s13318-020-00613-9
The quality of articles published in the journal is also reflected in its most recent impact factor (2019 impact factor 1.913). The quality of published articles is also testament to the significant efforts of the peer reviewers, whose willingness to share their expertise ensures that the journal’s content is held to the highest possible stand
Data Loading...
